Therapeutic Response

v::ROS1 status confers therapeutic sensitivity to Entrectinib in patients with Non-Small Cell Lung Cancer.

Statements

Source and description
Rozlytrek (entrectinib) [product information]. EMA. The European Medicines Agency (EMA) has conditionally authorized entrectinib for the treatment of adult patients with ROS1-positive advanced non-small cell lung cancer (NSCLC) not previously treated with ROS1 inhibitors.
Entrectinib Monotherapy - Adult. NCCP National SACT Regimen. HSE. The Republic of Ireland's Health Service Executive (HSE) has approved entrectinib for reimbursement as a monotherapy treatment option for adult patients with ROS1-positive, advanced non-small cell lung cancer (NSCLC) not previously treated with ROS1 inhibitors.
Rozlytrek (entrectinib) [package insert]. FDA. The U.S. Food and Drug Administration granted approval to entrectinib for the treatment of adult patients with ROS1-positive metastatic non-small cell lung cancer (NSCLC), as detected by an FDA-approved test.